Company intelligence / Profile preview

X-Vax Technology

Palm Beach Gardens, Florida, United States

Ownership: Private
Employees: ~30
Development stage: Other

Overview

Preclinical vaccine candidate delta gD-2, an HSV-2 virus with deleted glycoprotein D (gD-2), showed prevention of HSV-1 and HSV-2 infections and induction of sterilizing immunity in preclinical models by eliciting antibodies that kill infected cells.

Therapeutic areas: Infectious Diseases
Modalities: Vaccine
Industry: Biotech

Drug pipeline

1 asset

∆gD-2

Unknown

Partnerships

Serum Institute of IndiaJohnson & Johnson Innovation

Beyond the preview

Go deeper on X-Vax Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on X-Vax Technology.

Explore the full profile